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S U M M A R Y
The Gram-negative bacterium Pseudomonas aeruginosa is one of the most common opportunistic
pathogens, especially after liver transplantation. Pathophysiological alterations of liver sinusoidal
endothelial cells (LSECs) have far-reaching repercussions on the liver and on metabolism. LSECs are
perforated with fenestrations, pores that facilitate the transfer of lipoproteins and macromolecules
between blood and hepatocytes. Gram-negative bacterial endotoxin (lipopolysaccharide, LPS) and the P.
aeruginosa toxin, pyocyanin, have marked effects on LSECs. Initial loss of LSEC porosity (defenestration)
induced by P. aeruginosa pyocyanin and LPS may confer subsequent immune tolerance to circulating
bacterial antigens and toxins. This review collates the known immune responses of the liver to Gram-
negative bacterial toxins, with a focus on LSECs. Hyperlipidemia is an important response to Gram-
negative bacterial sepsis. The mechanisms proposed for sepsis-associated hyperlipidemia include tissue
lipoprotein lipase inhibition and upregulated hepatic triglyceride production. In this review, we propose
defenestration of the LSECs by bacterial toxins as an additional mechanism for the hyperlipidemia of
sepsis. Given the role of LSECs in hyperlipidemia and liver allograft rejection, LSEC changes induced by P.
aeruginosa toxins including LPS and pyocyanin may have signiﬁcant clinical implications.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Pathologic and morphologic alterations of the liver sinusoidal
endothelial cell (LSEC) have far-reaching repercussions for the liver
and for systemicmetabolism because of its strategic position in the
liver sinusoid. LSECs are perforated with fenestrations, which are
pores that facilitate the transfer of lipoproteins and macromole-
cules between the blood and hepatocytes. Loss of LSEC porosity is
termed defenestration, which can result from loss of fenestrations
with or without decreases in fenestration diameter. Sepsis is
associated with hyperlipidemia, and mechanisms proposed
include inhibition of tissue lipoprotein lipase and increased
triglyceride production by the liver. However, LSECs have also
been increasingly recognized to play a signiﬁcant role in
hyperlipidemia. Pertaining to this important role, Gram-negative
bacterial endotoxin (lipopolysaccharide, LPS) and Pseudomonas* Corresponding author. Tel.: +61 0406 0406 20; fax: +61 02 9385 1389.
E-mail address: r.cheluvappa@unsw.edu.au (R. Cheluvappa).
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morphology and function. Additionally, conditions presentingwith
LSEC defenestration such as aging and bacterial infections are
associated with impaired lipoprotein and chylomicron remnant
uptake by the liver and hyperlipidemia.
P. aeruginosa infection is an increasingly important cause of
sepsis and death in organ transplant recipients, particularly those
receiving liver transplants126,176. P. aeruginosa has a special afﬁnity
for tissue vasculature, typically surrounding blood vessels
circumferentially (perivascular cufﬁng) during infection1,2 or
congregating in postcapillary venules.3 In vitro studies show that
P. aeruginosa induces apoptosis in the cultured endothelial cell line
ECV304,4,5 suggesting that it might also contribute to loss of
endothelium in vivo.
P. aeruginosa produces a number of virulence factors including
pyocyanin, a tricyclic phenazine derivative with a broad activity
spectrum including redox activity6,7 with production of reactive
oxygen species (ROS),8 immunomodulatory9,10 and pro-inﬂam-
matory effects,11 inactivation of succinic dehydrogenase,12 cyto-
toxicity,6,11 and induction of apoptosis13 and senescence.14ses. Published by Elsevier Ltd. All rights reserved.
R. Cheluvappa et al. / International Journal of Infectious Diseases 14 (2010) e857–e867e858Pyocyanin induces oxidative stress and morphological changes in
endothelial cells.15,16 Hepatic LSECs are sensitive to both oxidative
stress17 and the effects of LPS18,19 and pyocyanin.16,20 Owing to the
role of the LSEC in liver allograft rejection21 and hyperlipid-
emia,22,23 cellular and biochemical changes induced by Gram-
negative bacterial toxins may have signiﬁcant clinical import.
This review collates the known immune responses of the liver
to Gram-negative bacterial toxins, with a focus on LSECs, and
summarizes up-to-date information on LSECs in relation to the
cellular pathogenesis of LPS and P. aeruginosa toxins in inducing
sepsis-related hyperlipidemia in Gram-negative bacterial sepsis.
2. The liver lobule and LSECs
The lobule is the structural and functional unit of the liver. Each
lobule consists of parenchyma with hepatocytes supplied by the
smallest portal tracts containing portal vein radicles, hepatic
arterioles, and bile ductules (Figure 1). The portal tract for each
lobule is called the portal triad. The hepatic sinusoids that carry
blood from the hepatic portal vein and the hepatic artery emanate
from the portal triad and radiate outwards. The hepatocytes are
drained by the central veins, also called terminal hepatic veins. The
hepatocytes surrounding the portal triads (periportal area, zone 1)
are supplied with oxygenated blood, and are more resistant to
hypoxia and ischemic injury than the hepatocytes distributed
around the central veins (pericentral area, zone 3).
Four types of cells constitute the hepatic sinusoid, LSECs,
Kupffer cells (KCs), stellate cells (SCs), and pit cells, each with
speciﬁc morphology and function (Figure 1). LSECs make up
approximately 20% of hepatic cells, KCs around 15%, and SCs
around 5%. Depending on the disease process, each cell type can
undergo speciﬁc changes.24
LSECs, which line the liver sinusoidal capillary lumen, regulate
the passage of substances to and fro from the blood. KCs, which are
modiﬁed macrophages attached to the endothelium, phagocytose[(Figure_1)TD$FIG]
Figure 1.Hepaticmicrocirculation and the liver sinusoid. Structure of the liver sinusoid:18
and sinusoids showing a branch of the portal vein (PV) and branch of the hepatic artery
into the sinusoids is shown ("). (B) Scanning electron micrograph of liver; Kupffer cel
sinusoidal endothelial cell (LSEC) layer is thin and perforated with fenestrations (F). Theand degrade gastrointestinal particles with antigenic components
as well as bacteria and toxins that are carried via the portal vein to
the liver.25,26 KCs also assist in tissue repair and clearance of
senescent and damaged erythrocytes, and are involved in antigen
presentation to T and B lymphocytes.27 SCs, which are located in
the space of Disse, store fat and vitamin A, and probably inﬂuence
hepatic sinusoidal blood ﬂow and play amajor role in the synthesis
of extracellular matrix, especially in cirrhotic livers.24 Pit cells, a
form of natural killer (NK) cells, possess azurophilic granules and
exhibit tumoricidal cytolysis.24
3. LSECs are a key component of the liver sieve apparatus
The walls of the hepatic sinusoid are lined by LSECs and lack a
basement membrane,24,28 and possess fenestrations with dia-
meters ranging from 100 to 200 nm.24,29 LSEC fenestrations are
visible on electron microscopy as circular or oval perforations
arranged in sieve plates within the thin extensions of the
cytoplasm30 (Figure 1). Both fenestrations and sieve plates are
structurally delineated by cytoskeleton elements.31 The suben-
dothelial space that lies between the sinusoids and hepatocytes is
called the space of Disse and contains a low-density matrix of
basement membrane constituents and SCs (Figure 1). The LSECs,
which contain fenestrations arranged in sieve plates, and the
subendothelial space of Disse, containing extracellular matrix,
together constitute the liver sieve. Since LSECs have fenestrations
and lack basement membrane, substrates from the sinusoidal
lumen can translocate directly through the fenestrations to the
low-density matrix of the space of Disse, to make contact with
hepatocyte microvilli, and vice versa.24,32 Blood constituents that
are too large to pass through fenestrations such as erythrocytes
and chylomicrons are excluded from the space of Disse, while
smaller molecules including smaller lipoproteins such as chylo-
micron remnants are able to pass directly through the fenestra-
tions.337 (A) Scanning electronmicrograph of a vascular cast of the hepaticmicrocirculation
(HA) with surrounding sinusoidal microvascular network (S). A branch from the PV
l (KC) lying in a sinusoid. (C) Transmission electron micrograph of liver; the liver
extension of a stellate cell (HSC) lies beneath the liver sinusoidal endothelial cell.
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and fenestration diameter. The total area covered by the
fenestrations has been estimated to account for approximately
10% of the LSEC surface area.33 The natural porosity of the hepatic
sinusoids increases from the portal triad (zone 1) towards the
central vein (zone 3) owing to a slight increase in fenestration
frequency,34,35 and perhaps also an increase in fenestration
diameter.34,36 Vidal-Vanaclocha and Barbera-Guillem classiﬁed
fenestrations into two types, clustered pores, which are more
prevalent in the pericentral sinusoids, and free pores, which are
more prevalent in the periportal sinusoids.36
Utilizing ‘endothelial massage’, erythrocytes and leukocytes
may ﬂush plasma through the fenestrations in the endothelium.29
Permeation selectivity of different molecules is regulated by the
fenestration sizes, the molecule sizes, and the transport kinetics of
the molecules relative to steric and frictional properties of the
fenestrations. Therefore, passage of small sized particles like
albumin (7 nm diameter) is probably not size-limited in the
normal liver. However, passage of larger molecules like IgM
antibodies (10–20 nm diameter) may be size-limited.
Alterations in fenestration diameter or fenestration frequency
can affect exchange of plasma across the sinusoidal lumen and the
space of Disse, inﬂuencing liver function.30 Loss of LSEC porosity is
termed defenestration. In speciﬁc pathological processes, defen-
estration occurs along with endothelial thickening and deposition
of excessive extracellular matrix in the subendothelial space of
Disse. These changes, called capillarization in cirrhosis and
pseudocapillarization in aging, pose an impediment to the transfer
of many substrates from the sinusoidal lumen to the hepatocytes
through the space of Disse.
4. LSEC fenestration morphology and the role of the
cytoskeleton in fenestration formation and regulation
LSEC fenestrations (Figure 1) are inducible structures and the
cytoskeleton is involved in their formation.37,38 Each fenestrationTable 1
Effect of commonly exposed agents and pathogenic processes on liver sinusoidal endo
Treatment agent Porosity % Fenestration
diameter
Autonomic and vasoactive agent regulation
1 Acetylcholine "
2 Noradrenaline #
3 5-Hydroxytryptamine (serotonin) # #
4 Endothelin 1 #
5 ETA-R antagonist (BQ123) #
6 Prostaglandin E1 "
7 Pantethine " "
Alcohol or nicotine exposure
8 Ethanol " "
9 Ethanol (chronic) #
10 Nicotine # #
Exposure to agents present occasionally in the environment
11 Dimethylnitrosamine (processed meat) #
12 Poloxamer 407 (various products) #
Pathological processes
13 Aging #
14 Cirrhosis #
15 Post-hepatic inferior vena cava occlusion " #
16 Portal hypertension "
17 Paracetamol overdose "
Ca2+, calcium ion; cAMP, cyclic adenosine monophosphate; ETA-R, endothelin receptoris circumscribed by a ﬁlamentous, fenestration-associated cyto-
skeleton ring composed of actomyosin components39 with an
average ﬁlament thickness of around 16 nm.31 The sieve plates,
which enclose the fenestrations, are encircled by microtubules.
The sieve plates and the fenestrations are then linked to the
cellular cytoskeleton. Agents that alter the sieve plate structure
and porosity induce cytoskeletal changes and vice versa.38
5. Effect of endobiotics, xenobiotics, and pathophysiological
processes on LSEC fenestrations and liver sinusoidal
endothelial porosity
Some endogenous and exogenous agents and pathophysiologi-
cal conditions that alter LSEC fenestrations are summarized in
Table 1.
5.1. Autonomic regulation and cellular mediators
Hormones of the autonomic nervous system have effects on
LSEC fenestration dimensions. Acetylcholine dilates LSEC fenestra-
tions, while noradrenaline constricts them.40,41 Serotonin (5-HT)
increases intracellular calcium, leading to myosin light chain
phosphorylation and constriction of fenestrations.38,42 Similarly,
Ca2+ and adenosine triphosphate (ATP) have been shown to
constrict fenestrations, thereby reducing porosity.42–44 Addition-
ally, the Ca2+–calmodulin–actomyosin system has been implicated
in the structural regulation of LSEC fenestrations.39 These ﬁndings
indicate that fenestration contraction is an active processmediated
via LSEC Ca2+.
5.2. Alcohol or nicotine exposure
Acute andmedium-term exposure to alcohol in rats in vivo or in
isolated LSECs in vitro is associated with increased diameter,
frequency, and porosity of LSEC fenestrations.38,45–48 In contrast,
with chronic long-termalcohol intake, humans49 andmice48 displaythelial cell fenestrations
Fenestration
frequency
Other changes Ref.
40, 41
40, 41
" Cell Ca2+, " cAMP changes blocked
by Ca2+ chelation or Ca2+ channel blocker
38, 42
171
# 172
171
" 173
" 38, 45–48
# Hepatic steatosis 48, 49
– Hypercholesterolemia 52
32
# No ATP changes, no mitochondrial
dysfunction
53
# # Mass, # blood ﬂow, " endothelial
thickening, pseudocapillarization
23, 61, 62, 64
# Cirrhotic nodules, " endothelial
thickening, capillarization
22, 23, 50, 51
", "" 56
" 57
55
type A; ATP, adenosine triphosphate.
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transmissionof larger chylomicrons across the LSECswith acute and
medium-term alcohol consumption may be a crucial step in the
pathogenesis of alcoholic hepatic steatosis.47 Alcoholic liver disease
can have three overlapping sequential phases, namely hepatic
steatosis, alcoholic hepatitis, and cirrhosis. It is possible that
following short-term/medium-term alcohol consumption after
the steatosis/hepatitis phase where the LSEC porosity is increased,
and prior to the cirrhotic phase of alcoholic liver disease where the
LSEC porosity is decreased, LSEC defenestration commences. LSEC
defenestration has been shown to occur early in the pathogenesis of
cirrhosis in patients suffering from chronic alcohol abuse,49
accompanied by hyperlipoproteinemia.50 LSEC defenestration also
occurs in animal models of cirrhosis.23,51
Nicotine decreased LSEC porosity to about 40% of that of control
animals and induced hypercholesterolemia.52
5.3. Exposure to environmental agents
The hepatic carcinogen dimethylnitrosamine, which is found in
processed meat, induces defenestration.22 The detergent polox-
amer 407 induces loss of LSEC porosity by decreasing the
fenestration frequency with no changes in ATP or mitochondrial
function, and with marked associated hyperlipidemia.53
5.4. Pathophysiological and toxicological processes
Cirrhosis and aging are also associated with marked structural
changes in the sinusoidal endothelium and the space of Disse that
inﬂuence bulk plasma transfer into the space of Disse, through the
LSECs.23 Capillarization associated with cirrhosis differs from
aging-associated pseudocapillarization by having additional fea-
tures of bridging ﬁbrosis or nodular regeneration, periportal or
pericentral ﬁbrosis, loss of hepatocyte microvilli, and only minor
deposits of collagen in the space of Disse. These changes impede
the transfer of many substrates including chylomicron remnants,
albumin, protein-bound drugs, and other macromolecules to the
hepatocytes via the space of Disse.54
Paracetamol overdose dilates fenestrations and causes the
generation of large gaps.55 Post-hepatic inferior vena cava
occlusion markedly dilates fenestration diameter, while decreas-
ing the fenestration frequency.56 Artiﬁcial high perfusion pressure
through the hepatic portal vein simulating portal hypertension
dilates fenestrations, and results in the trapping of large
chylomicrons.57 This particular study also suggests a possible
mechanism in the hepatic steatosis seen in the ‘nutmeg liver’ of
chronic venous congestion.
The vascular and liver sinusoidal endothelial complications of
diabetes including LSEC defenestration are well established and
are clinically signiﬁcant.58,59 With aging, there is a substantial loss
of fenestrations in the LSEC,60–63 which impairs lipoprotein
transfer to the hepatocyte.64 Thus there are potential parallels
between age-related dyslipidemia and diabetes mellitus-related
dyslipidemia.65–67
Alterations in number, frequency, distribution and diameter of
fenestrations by hormones, xenobiotics, hepatotoxins, and dis-
eases have important ramiﬁcations for hepatic microcirculation,
substrate handling, drug metabolism, and overall function.
Chylomicrons (100–1000 nm diameter) are too large to pass
through the fenestrations.68 Only partially catabolized chylomi-
crons (chylomicron remnants) attain individual dimensions small
enough to pass through the fenestrations into the space of
Disse.54,69 In defenestration caused by cirrhosis,22,23,50 normal
aging,23,61,62,64 or with treatment with detergents like poloxamer
407,53 distribution of chylomicron remnants was excluded from
the space of Disse.536. Immunological functions of the liver: the hepatic immune
response to Gram-negative bacterial toxins
6.1. The liver and gastrointestinal bacterial antigens
The liver is the ﬁrst organ that encounters pathogens and
pathogen-derived products from the gut. For example, alcohol-
induced gut permeability liberates LPS from gastrointestinal
Gram-negative bacteria.70 Most Gram-negative bacteria including
P. aeruginosa have LPS as a component of their outer cell walls. LPS
is present in normal portal blood at concentrations of 10 pg/ml to 1
ng/ml.71 In one study performed on samples from 34 elective
abdominal surgery patients, 97% of the patients had LPS in their
portal blood, demonstrating that LPS is present normally in portal
blood and is not necessarily pathogenic.72 In this study, systemic
endotoxemia was observed in three of the four patients who also
had liver disease. None of the patients without liver disease had
endotoxemia. In cirrhosis, there is augmented LPS uptake by the
liver and increased biliary excretion of LPS.73
Immunologically active liver cells include KCs, LSECs, neutro-
phils, and lymphocytes, and perhaps the hepatocytes them-
selves.27,71 The liver also acts as a ﬁlter or a ‘sieve’ for bacteria
and antigens carried from the gastrointestinal tract. These antigens
are phagocytosed and degraded by KCs and LSECs.25 The near
complete absence of lymphoid tissue in the liver implies that
antigens are degraded herewithout the production of antibody.27,71
The antigens are thus precluded from reaching other antibody-
producing sites in the body, thereby preventing adverse systemic
hypersensitivity. Thus the liver favors the induction of tolerance
rather than the induction of immunity.27,71 Different liver cell types
contribute in different ways to induce liver antigenic tolerance.
These include control of antigen presentation (immune ignorance),
clonal deletion, and immunedeviation.Naive T cells are activatedby
LSECs, but do not differentiate into effector T cells. These T cells
demonstrate a functional phenotype and cytokine induction proﬁle
typical of tolerance induction.74Dendritic cells (DCs), LSECs, KCs and
hepatocytes also contribute to tolerance induction by deletion of T
cells through induction of apoptosis.71 Recently, the mechanical
contribution of LSECs in the development of immune tolerance has
also beenwell demonstrated. Resident and circulating lymphocytes
make direct contact with hepatocytes via LSEC fenestrations using
cytoplasmic extensions.75 Hepatocyte MHC class I and ICAM-1
molecules, which are necessary for T cell activation, have been
shown to be polarized on the perisinusoidal side of the hepatocellu-
lar membrane apparently to maximize interaction with blood
lymphocytes.75 Corroborating this is the fact that LSEC defenestra-
tion at an earlier time-point of mouse model of immune-mediated
hepatitis signiﬁcantly attenuates subsequent liver damage in the
same model, pointing to LSEC defenestration modifying hepatic
immunological responses.76
6.2. KC activation
KCs are predominantly located in the periportal area. They
assist in tissue repair, T and B lymphocyte interaction, and
cytotoxic activity in disease processes.77 KCs are antigen present-
ing cells thatmodulate immune responses, induce oral tolerance to
bacterial superantigens, and suppress T-cell activation by antigen-
presenting LSECs, prostanoids, and tumor necrosis factor-a (TNF-
a).71,78 Upon activation, KCs secrete interleukins (IL), chemokines,
TNF-a, collagenase, and lysosomal hydrolases. During acute
hepatic insult, KCs secrete enzymes and cytokines that damage
hepatocytes, and are active in the remodeling of extracellular
matrix. Granulocyte-colony stimulating factor (G-CSF) is a nega-
tive feedback signal for macrophage-derived TNF-a production
after LPS-induced hepatotoxicity.79
R. Cheluvappa et al. / International Journal of Infectious Diseases 14 (2010) e857–e867 e861Following LPS-stimulation, KCs release IL-6, IL-8, and other
chemokines, as well as TNF-a, which induce liver parenchymal
damage. These cytokines also stimulate LSECs, SCs, and NK cells to
release pro-inﬂammatory cytokines, thus exacerbating the dam-
age.27 Exposure of KCs to LPS can lead to intense inﬂammatory
mediator production, and subsequently liver injury. KCs are
involved in the initial hepatic insult, followed by neutrophils in
the latter phase of hepatic injury.80,81 Both cell types liberate ROS
to inﬂict the injury.81–83 Alcohol increases gastrointestinal tract
permeability, liberating LPS from gut bacteria into the blood
stream, which in turn activate KCs. KCs and gastrointestinal tract-
derived LPS are crucial in the pathogenesis of alcohol-induced
hepatotoxicity.70 Long-term alcohol exposure changes KC sensi-
tivity to LPS.84 TNF-a plays a key role in the pathogenesis of
hepatic injury in response to LPS. Leukotriene D4 and ROS precede
TNF-a action in the induction of LPS-induced hepatitis in the
murine endotoxin/galactosamine TNF-a model.85,86
6.3. The liver, bacterial antigens and ROS
Most antioxidant mechanisms are upregulated by LSECs in
response to LPS, including H2O2-detoxifying capacity,
87 LSEC
glutathione (GSH) efﬂux mechanisms,88 glucose transporter 1
(GLUT1), glucose-6-phosphate dehydrogenase (G6PD),89 superox-
ide dismutases (SODs), and glutathione peroxidase (GPx).90
Superoxide generation in the hepatic sinusoid in response to
LPS challenge is likely to be a factor involved in liver damage.91
6.4. The liver, coagulation system and gastrointestinal bacterial
antigens
In one murine model study, co-administration of non-hepato-
toxic doses of the commonly used H2 receptor-blocker ranitidine
and LPS activated the clotting system via over-expression of
plasminogen-activator inhibitor-1 (PAI-1), with ﬁbrin deposition
in the liver and hepatocyte damage.92,93 Thrombin is a promoter94
and a distal mediator95 of LPS-induced hepatotoxicity. LPS induces
decreased LSEC thrombomodulin, which results in sinusoidal
microthrombus formation and exacerbation of hepatic injury.96
Platelets97 and the coagulation cascade98 contribute to LPS-
induced hepatic injury. KCs play an important role in LPS-induced
sinusoidal thrombogenesis, ﬁbrin degradation and deposition.99
6.5. Other hepatic responses to gastrointestinal bacterial antigens
LPS alters the membrane ﬂuidity of hepatocytes.100 LPS may
inﬂuence hepatocyte–macrophage communications,101 which in
humans may lead to a transient increase in liver insulin-like
growth factor in addition to transient increases in cortisol and
pituitary growth hormone, similar to changes seen in acute
trauma.102 In the isolated perfused rat liver model, LPS induces
cholestasis without signiﬁcant hepatic damage, which suggests a
possible role for extrahepatic mechanisms for induction of liver
damage.103 LPS is a potent stimulator of hepatocyte ﬁbronectin,
which suggests that hepatocytes may also be directly involved in
liver ﬁbrosis.104 LPS also synergizes with monocrotaline,105
aﬂatoxin B1,106 polychlorinated biphenyls,107 and a range of liver
toxins like carbon tetrachloride, ethanol, cadmium, halothane and
allyl alcohol,108 in causing hepatic injury.
7. The role of LSECs in liver immunology
7.1. LSECs and antigen processing
LSECs are crucial to processing, scavenging, and tolerance
induction responses to gastrointestinal antigens as well ascirculating systemic antigens. LSECs constitutively express all
molecules necessary for antigen presentation (CD40, CD54, CD80,
CD86, MHC-I and MHC-II) and function as MHC-I and MHC-II
restricted antigen-presenting cells (APC).27,71,74,109 LSECs also
exhibit antigenic resemblance to dendritic cells by expressing
CD4, themannose receptor, and CD 11C.110–113 LSECs are very good
antigen presenting cells and have been shown to induce
proliferation, co-stimulation, and upregulation of cytokine pro-
duction in CD4+ T cells.111,114
7.2. LSECs and T cell interactions
LSECs regulate the recruitment of speciﬁc lymphocyte sub-
types. CD4 and CD8 T cells that simultaneously interact with LSECs
have a tolerant phenotype.115 They suppress interferon-g produc-
ing cells and promote IL-4-expressing helper T cell subset 2 (Th2)
cells, creating immune suppression in the liver.116 LSEC primed
CD4+ T cells differentiate into regulatory T cells, whereas
myelocytic APC primed T cells differentiate into helper T cell
subset 1 (Th1) cells.117 Therefore, LSEC primed CD4+ T cells play a
crucial role in tolerance induction in the liver. The CD4+ T cell
priming activity of LSECs can be negatively regulated by
prostaglandin E2 (PGE2) and IL-10.111 LSECs also play a role in
the development of tolerance by CD8 T cells towards orally
administered antigens.118 LSECs are also important in tolerance
induction in liver transplantation. In one study, the rejection of
donor livers correlated closely with the presence of anti-LSEC
antibodies, increased activation of T cells, and decreased trans-
forming growth factor-b (TGF-b).21
7.3. LSECs and antigen scavenging
In addition to antigen processing, LSECs scavenge antigens such
as LPS and advanced glycation end-products.115,119–121 Scavenging
is distinctly different from antigen processing. LSECs endocytose
glycoproteins, extracellular matrix components, immune com-
plexes, transferrin, and ceruloplasmin, thereby clearing antigens
from the vasculature.122
7.4. LSECs and immune surveillance
LSECs may assist immune surveillance via T cell activation,
which in turn is inﬂuenced by the milieu encompassing bacteria
and LPS. LSECs express CD14, which serves as a receptor for the LPS
binding protein.109,123 LSECs also assist immune surveillance by
releasing immunosuppressive mediators such as IL-10, PGE2, and
TGF-b.21,71,111
8. Pseudomonas aeruginosa infections and the liver
8.1. Clinical impact of Pseudomonas aeruginosa infections
P. aeruginosa is a common nosocomial bacterial pathogen
associated with a high incidence of post-operative morbidity and
mortality.124 Studies that describe P. aeruginosa as one of the most
common multi-antibiotic resistant nosocomial organisms, espe-
cially in post-surgical and post-liver transplant scenarios, are
shown in Table 2. Post-operative pseudomonal infections, includ-
ing P. aeruginosa infections after liver transplantation,124–126 can
result in sepsis,127,128 bacteremia,125,126 hepatic damage,129,130
and fatal multiple-organ failure.127,128
8.2. Pseudomonas aeruginosa toxins and the liver
Pyocyanin, a redox-active, pro-inﬂammatory, pro-apoptotic,
cytotoxic and immunomodulatory tricyclic phenazine metabolite
Table 2
Incidence of Pseudomonas aeruginosa in post-surgical and post-liver transplant infections
Study dates Patient cohort Cohort
size
Pathogen parameter
examined
Cohort % with
parameter
present
Incidence of
pseudomonal
infections
Pathology speciﬁcs Ref.
2000–2003 Liver transplant 30 Bacteremia 30% 44% of bacteremia 100% with bacteremia died 174
1999–2003 Liver transplant 103 Bacterial pneumonia 32% 17% of pneumonia 50% with pneumonia had
acute rejection
175
1989–2003 Liver transplant 233 Bacteremia 52% Topmost 126
2001–2002 Living donor liver
transplant
113 Surgical site infection 37% 33% of Gram-negative
bacterial infections
26% with surgical site
infection died
125
1999–2002 Liver transplant 99 Multiple antibiotic
resistance
57% 23% of all bacterial
infections
63% of all infections by
multi-antibiotic resistant
bacteria
124
1998–2001 Liver transplant 401 Pneumonia 5% >57% of pneumonia 176
1990– 1999 Liver transplant 165 Multiple antibiotic
resistance
31% 50% of multi-antibiotic
resistant bacteria
Higher mortality 177
1995–1998 Liver transplant
in ICU
90 Pulmonary inﬁltration 40% 27% of pneumonia 38% with inﬁltrates had
pneumonia
178
1990– 1995 Liver–lung–heart
transplant in cystic
ﬁbrosis
10 Double organ transplants 100% 100% multi- antibiotic
resistant
179
1990–1993 Liver transplant 284 Aerobic Gram-negative
bacteria
45% Most frequently isolated
from blood
180
1988–1991 Liver transplant 185 Bacteremia and fungemia 29% 10% of bacteremia
and fungemia
95% of all infections
nosocomial
181
1985–1991 Kidney transplant 568 Bacteremia and fungemia 11% 19% bacteremia
and fungemia
70% of all infections
nosocomial
181
1981–1984 Liver transplant 129 Early death >24 h 37% 53% of deaths due
to bacterial sepsis
Bacterial sepsis in 81%
of deaths
182
ICU, intensive care unit.
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Though systemic, portal, or hepatic concentrations of pyocyanin
have not been estimated in pseudomonal sepsis, it is well known
that it is present in large amounts (up to 130mM) in respiratory
secretions from cystic ﬁbrosis and bronchiectasis patients with P.
aeruginosa infections.131–133 Pyocyanin has been shown to exert its
in vivo and in vitro cytotoxicity by impairing the cellular redox
status and depleting intracellular GSH and thiols in endothelial
cells,8 and in transformed epithelial cells134 via superoxide and
H2O2 generation,
8,134 or through direct oxidation of GSH.134 Based
on known effects by oxidants on the cellular cytoskeleton,
pyocyanin-dependent increases in sinusoidal H2O2 could induce
modiﬁcations in the cellular actin cytoskeleton leading to altered
LSEC morphology.
The impact of LPS has already been discussed in earlier sections.
P. aeruginosa exotoxin A induces liver damage by protein
synthesis inhibition, activation of KCs to produce TNF-a, and
perforin-dependent, Fas-independent, apoptotic pathways.135 To
induce substantial hepatocyte damage, P. aeruginosa exotoxin A
requires the presence of T cells to stimulate KCs to secrete TNF-
a.77,135 For P. aeruginosa exotoxin A to synergizewith LPS to induce
severe hepatotoxicity, T cells are required to produce circulation of
sustained high concentrations of TNF-a.78
8.3. LSECs and LPS
When LSECs are incubatedwith LPS, speciﬁc immune responses
by CD4+ cells are down-regulated.74 LPS also induces LSEC
scavenger and endocytotic functions119 and subsequently antigen
presentation to lymphocytes.111,114 LPS can also induce sinusoidal
thrombogenesis, ﬁbrin degradation and deposition,99 as well as
LSEC apoptosis via TNF secreted by KCs.136
LPS defenestrates LSECs.32 One intravenous dose of LPS (2 mg/
kg body weight stat) in Dark-Agouti rats reduced LSEC porosity
signiﬁcantly, the changes being spontaneously reversed after 14
days.With the same LPS dose, Sprague-Dawley rats showed similar
but irreversible changes at least 3 days after LPS challenge.18
Intravenously injected LPS (2.5 mg/kg body weight) in F344 ratsresulted in LSEC enlargement, sieve plate disruption, and gap
formation 6 h after LPS challenge.19 KCs seem to modulate LPS-
induced LSEC defenestration and impaired hyaluronan scaveng-
ing.137 Takei and co-workers reported that co-incubation of LSECs
with LPS-stimulated KCs induced signiﬁcant apoptosis in LSECs
that come in contact with KCs. Anti-TNF-a antibody prevented the
LPS-induced apoptosis.136
Alcohol abuse may promote the uptake of LPS from alcohol
lysed gut bacteria or from direct injury to the intestinal wall.70 LPS
could induce liver damage starting with the LSEC18 or secondary to
KC and neutrophil70,138 activation. This could be a pivotal
pathogenic factor in alcoholic cirrhosis.
8.4. LSECs and pyocyanin
Given the role of LSECs in liver allograft rejection21 and
hyperlipidemia,22,23 changes in the LSEC induced by pyocyanin
may have signiﬁcant clinical implications. As P. aeruginosa
pyocyanin has been shown to deplete intracellular GSH and thiols
in endothelial cells,8 the possibility that P. aeruginosa pyocyanin
may impact LSEC structure and function by impairing the cellular
redox status via generation of H2O2 and ROS and depletion of
intracellular GSH and thiols was explored.
In our study exploring the effects of pyocyanin on isolated
LSECs,20 we showed that pyocyanin treatment over a wide range of
concentrations substantially reduced LSEC porosity. In our earlier
study,16 we showed that catalase, which inactivates H2O2 to water,
prevented pyocyanin-induced morphological changes including
defenestration in the LSECs, suggesting a role for oxidative cellular
injury in cellular pathogenesis of pyocyanin. However, in our study
in intact in situ rat livers,20 portally injected pyocyanin (blood
concentration of 12 mM for 30 min) induced a signiﬁcant loss of
porosity and a novel ﬁnding, endothelial thinning, without
immunohistochemical evidence of changes in the well-character-
ized markers of oxidative change, malondialdehyde and 3-
nitrotyrosine. As the latter in vivo ﬁndings appear to have the
contradistinctive veneer to the former in vitro studies, it is
plausible that in vivo, hepatocyte-derived antioxidants prevented
R. Cheluvappa et al. / International Journal of Infectious Diseases 14 (2010) e857–e867 e863overall changes in markers of oxidative stress, but the magnitude
of the same was insufﬁcient to prevent LSEC defenestration.
Alternatively, it is possible that pyocyanin induces defenestration
through mechanisms independent of oxidative stress. Using
immunoblot binding-mobility and immunohistochemical techni-
ques, we ruled out any role for caveolin-1, an important
fenestration membrane protein that changes with fenestration
changes.20 As pyocyanin has been shown to inﬂuence the
expression and secretion of numerous cytokines,9,139 further
investigations into the expression and activity of these cytokines
may serve to unravel the appropriate mechanisms. Our studies
point to the LSECs as the initial site of pyocyanin-induced injury,
and indicate the sentinel role of LSECs in protecting hepatocytes
from endo- and xenobiotics.
In addition to a sentinel role for LSECs in hepatoprotectivity
from bacterial toxins, there is a possibility that initial LSEC
defenestration induced by P. aeruginosa pyocyanin and LPS may
confer immune tolerance to circulating bacterial antigens and
toxins, as it has been shown that early LSEC defenestration
attenuates subsequent immune liver damage, pointing to LSEC
defenestration as possibly a signiﬁcant change in modifying
hepatic immunological responses.76
9. Hyperlipidemia of sepsis, bacteremia, and Gram-negative
bacterial toxemia
Sepsis is associatedwith free radical induction,140 altered redox
balance,127,128,141 cellular NADH/ATP reduction,127 cellular cyto-
skeletal modiﬁcations, and decreased hepatic energy metabo-
lism.127,128,142,143 Strikingly similar changes can also be induced by
Gram-negative bacterial toxins, either LPS88,91,144–146 or pyocya-
nin8,12,15,134,147–152 alone. Conditions including the presence of
free radicals and cytoskeletal modifying agents are particularly
conducive to LSEC defenestration.
It is possible that LSEC defenestration induced by bacterial
toxins such as LPS or pyocyanin may impede hepatic uptake of
chylomicron remnants and increase their circulation time, leading
to the hyperlipidemia of sepsis frequently reported in the
literature.153,154 Owing to this possibility, though it may not be
immediately apparent that hyperlipidemia could be an index of
altered lipoproteins from the portal system in clinical sepsis, the
role of this mechanismmay be as important, if not more important
than the other possibilities elaborated below, including (1)
suppression of peripheral lipoprotein lipase synthesis and activity,
(2) enhanced catabolism of adipose tissue, and (3) increased
hepatic lipoprotein turnover, modiﬁcation, and egress. The
currently accepted hypothesis for the pathogenesis of sepsis-
associated hypertriglyceridemia posits that sepsis stimulates
catecholamine release, which stimulates release of free fatty acids
from adipose tissue, which are taken up by the liver, metabolized
and then released as triglycerides in lipoproteins.142,154 Alterna-
tively, sepsis-stimulated TNF-a and IL-1 may suppress lipoprotein
lipase synthesis, which decreases the rate of triglyceride clearance,
leading to hypertriglyceridemia.142,154 Both LPS injection and
Escherichia coli bacteremia in rats result in hypertriglyceridemia
and decreased lipoprotein lipase activity. Experimental sepsis
stimulates liver putrescine and spermidine synthesis in addition to
ornithine decarboxylase activation, responses that can also be
simulated by LPS and pro-inﬂammatory cytokines.155 Therefore it
is clear that not only sepsis, but also recurrent Gram-negative
infections, bacteremia, and toxemia can lead to hypertriglycer-
idemia.
During endotoxemic states, one-third of LPS binds to high-
density lipoproteins and is taken up into peripheral tissues. The
remaining two-thirds are taken upmore rapidly, predominantly in
reticuloendothelial organs with abundant phagocytes, APCs, andcells with scavenger function.156,157 Increased serum high-density
lipoprotein and its LPS-binding capacity may serve to protect
against LPS-induced damage in chronic alcohol exposure.158,159
It has been shown that triglyceride-rich lipoproteins including
very low density lipoproteins and chylomicrons are capable of
binding LPS, forming lipoprotein–LPS complexes or chylomicron–
LPS complexes.154 These complexes modulate the host immune
responses and therefore impede LPS-induced toxicity. Chylomi-
cron–LPS complexes inhibit nitric oxide release by hepatocytes
much better than either of them alone, suggesting that chylomi-
cron-bound LPS inhibits hepatocyte nuclear factor-kappa B (NF-
kB) and prevents liver damage.160 Lipoproteins have also been
shown to protect animals from lethal polymicrobial Gram-
negative bacterial sepsis. Therefore it is possible that hypertrigly-
ceridemia could be an innate immune response to Gram-negative
sepsis.161 Alternatively, it could also be a possible mechanism to
perpetuate LPS-induced toxicity owing to prolonged systemic LPS
persistence.
10. A morphopathogenetic mechanism for the hyperlipidemia
of pseudomonal sepsis
Pyocyanin signiﬁcantly inﬂuences LSEC morphology and this
fact may have substantial clinical implications. LSECs are crucial in
tolerance induction in liver transplantation, and rejection of donor
livers correlates closely with the presence of LSEC antibodies.21
Additionally, the LSEC responses to ischemia–reperfusion injury in
the donor organ has been shown to alter the outcome of liver
transplantation.162,163 Following pseudomonal sepsis, damage to
the LSEC induced by pyocyanin could impact the graft outcome and
consequently the prognosis. As hyperlipidemia is an important
response to sepsis and as the mechanism for sepsis-associated
hyperlipidemia is multifactorial, impaired catabolism of lipopro-
teins is certainly a contributory factor.142,154 LSECs, which are
perforated with fenestrations that facilitate lipoprotein transfer
between blood and hepatocytes, have been increasingly recog-
nized to have a notable role in hyperlipidemia.22 Conditions
associated with LSEC defenestration such as aging64 and treatment
with the surfactant poloxamer 40753 are associated with impaired
lipoprotein uptake by the liver and hypertriglyceridemia. Although
it may not always be obvious that hyperlipidemia may be a
reﬂection of altered lipoprotein removal from portal blood, the
defenestration induced by pyocyanin supports the concept that
sepsis-related hyperlipidemia might at least in part be a result of
LSEC defenestration, alongside the other hypotheses described in
section 9, including increased delivery of triglycerides from the
liver, defective removal by peripheral tissues, andmodiﬁed plasma
lipoproteins. Pseudomonal sepsis with simultaneous release of
toxins like pyocyanin and LPS, may lead to endothelial changes
including loss of LSEC porosity, subsequently excluding lipopro-
teins from the liver, leading to lipoprotein retention in the
peripheral circulation. This mechanism may be crucial in the
contributory causality of sepsis-related hyperlipidemia (Figure 2).
11. Therapeutic possibilities in Gram-negative bacterial sepsis
LSEC fenestrations and liver sinusoidal porosity can be
regulated with a variety of physiological and pharmacological
agents (Table 1), as well as cytoskeletal manipulating agents
(Table 3). Morphological changes in liver sinusoidal fenestrations
have systemic implications particularly for lipoprotein metabo-
lism,164 clearance of medications,23 and immunity,75 as well as
conditional hepatoprotective effects.165
Endotoxemia alters Ca2+ homeostasis, with minute Ca2+ ﬂux
alterations.166 These changes, possibly due to catecholamine-
mediated Ca2+ inﬂux, are reversible by Ca2+ channel blockers.167
[(Figure_2)TD$FIG]
Figure 2. Probable pathogenesis of pseudomonal sepsis-related hyperlipidemia. Liver sinusoidal endothelial cell (LSEC) defenestration in bacterial/pseudomonal sepsis owing
to toxins like pyocyanin or endotoxin (lipopolysaccharide) may exclude lipoproteins from the liver leading to lipoprotein retention in the peripheral vasculature accounting
for bacterial/pseudomonal sepsis-related hyperlipidemia.
Table 3
Use of actin-disrupting agents to elucidate liver sinusoidal endothelial cell fenestration dynamics
Treatment agent Porosity Fenestration
diameter
Fenestration
frequency
Cytoskeletal changes Other changes Ref.
1 Antimycin A ### ### " Actin disassembly # ATP+ sieve plate protrusion 43
2 Cytochalasin B """ None, variable "" Actin disassembly + " polymerization FFCs not connected to fenestrations 37, 38,
183, 184
3 Latrunculin A # "" Actin disassembly + " polymerization FFCs not connected to fenestrations 183, 184
4 Misakinolide A # "" Actin disassembly + " polymerization FFCs connected to fenestrations 183, 185
5 Swinholide A # "" Actin disassembly + " polymerization FFCs not connected to fenestrations 183, 185
6 Jasplakinolide # " Actin disassembly + F-actin bundle
loss + " F-actin dots
FFCs not connected to fenestrations 183, 185
7 Hydrohalichondramide # "" Actin disassembly + " polymerization FFCs not connected to fenestrations 183, 186
8 Dihydrohalichondramide # "" Actin disassembly + " polymerization FFCs connected to fenestrations 183, 186
ATP, adenosine triphosphate; FFC, fenestration forming center.
R. Cheluvappa et al. / International Journal of Infectious Diseases 14 (2010) e857–e867864Under inducedendotoxemia, Ca2+ channelblockers limit hepatocyte
injury and inhibit LPS-induced KC inducible nitric oxide synthase
expression.168 LPS-induced membrane ﬂuidity of hepatocytes can
be prevented by Ca2+ channel blockers.100 Ca2+ channel blockers
curb the sepsis-induced acute phase response by preventing sepsis-
related hepatic Ca2+ changes140 that lead to reorganization of
fenestrations, and so modulate the metabolic response.
Pyocyanin or LPS trigger oxidant stress. This could lead to an
increased sinusoidal efﬂux of GSH and its extracellular oxidation.
GSH is depleted in LPS-mediated hepatic injury.88 Animal models
have shown that antioxidants such as GSH169 and adequate
nutrition170 are protective in septic shock. Superoxide generation
in the hepatic sinusoid in response to LPS challenge is likely to be a
factor involved in liver damage.91 Superoxide dismutase, which
dismutates superoxide to H2O2 has been shown to offer protection
against LPS-induced liver injury.140
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